Male breast cancer: a multicenter study to provide a guide for proper management.

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-11-01 Epub Date: 2024-06-19 DOI:10.1007/s10549-024-07380-0
Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti
{"title":"Male breast cancer: a multicenter study to provide a guide for proper management.","authors":"Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti","doi":"10.1007/s10549-024-07380-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To offer an extensive retrospective experience on the management of male breast cancer.</p><p><strong>Methods: </strong>A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.</p><p><strong>Results: </strong>In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).</p><p><strong>Conclusion: </strong>Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07380-0","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: To offer an extensive retrospective experience on the management of male breast cancer.

Methods: A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.

Results: In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).

Conclusion: Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
男性乳腺癌:一项多中心研究,为正确治疗提供指导。
简介:目的提供男性乳腺癌治疗的广泛回顾性经验:开展了一项多中心回顾性观察队列研究,包括1975年1月至2019年12月期间在意大利12个乳腺科确诊为乳腺癌(浸润性或原位)的男性患者。年满 18 周岁的患者均接受了资格评估。排除标准为确诊时为转移性癌症、曾患癌症、接受过新辅助治疗、(新)辅助治疗数据不完整和/或随访数据不完整。研究人员收集了放射学检查、人口统计学特征、风险因素、组织学特征、受体状态、治疗和随访数据:在一系列经过资格评估的 671 名男性乳腺癌患者中,有 403 名(28 名原位癌患者和 375 名浸润性肿瘤患者)被纳入研究。所有患者均接受了手术治疗。手术时的中位年龄为 63.8 岁(IQR 56.1-72.1)。68%的患者接受了超声波检查,55.1%的患者接受了乳房X光检查。大多数患者ER和PR阳性(63.8%),HER2阴性(80.4%),Ki67值高(≥20%)(61.3%),管腔B亚型(51.1%)。浸润性乳腺癌患者的10年总生存率为73.6%(95% CI 67.0-79.1),原位乳腺癌患者的10年总生存率为90%(95% CI 65.6-97.4)。在浸润性乳腺癌患者中,在单变量分析中,G3肿瘤(与G1相比)、pT2/3/4(与pT1相比)、pN2/3(与pN0相比)、Ki67≥20%的管腔B亚型(与管腔A相比)与较高的死亡风险显著相关。在多变量分析中,pT2/3/4(vs.pT1)仍与较高的死亡风险显著相关(HR 3.14,95% CI 1.83-5.39),HER2阳性或三阴性亚型(vs.管腔A)也与较高的死亡风险显著相关(HR 4.76,95% CI 1.26-18.1):男性乳腺癌是一种罕见疾病,有必要对其有更深入的了解,以便采取更有效的诊断和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
期刊最新文献
Current Review on Nanophytomedicines in the Treatment of Oral Cancer: Recent Trends and Treatment Prospects. Recent Updates on Phytopharmaceuticals-Based Novel Phytosomal Systems and Their Clinical Trial Status: A Translational Perspective. [Corrigendum] Tripartite motif‑containing 11 regulates the proliferation and apoptosis of breast cancer cells. [Retracted] Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells. [Retracted] Stimulation of peroxisome proliferator‑activated receptor γ inhibits estrogen receptor α transcriptional activity in endometrial carcinoma cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1